Method for primary prevention of allergic disorders during infancy through IgE-class-specific immunosuppression
US11827719B2 · kind B2 · utility
1Cited by
0References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 6, 2020 |
| Grant date | Nov 28, 2023 |
| Priority date | — |
| Expiry date | Dec 16, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/545
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.